Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5978)	3/20/2002 4:15:37 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

2 more firesales tomorrow???? +++++++ 16:01 ET Protein Design trial fails to meet primary endpoint (PDLI) 15.02 -0.99: Announces preliminary results from a Phase II clinical trial of psoriasis treatment, Zenapax (daclizumab) The results indicated that while Zenapax was well-tolerated, the antibody, at the dose levels administered, did not prolong the time to recurrence of psoriasis, the primary endpoint of the trial. "Based upon our initial analysis of the preliminary Phase II data, PDL does not plan to pursue additional development of daclizumab as a maintenance agent in psoriasis following treatment with other therapeutic agents." 15:59 ET Biopure press release questioned (BPUR) 11.20 +3.18: -- Update -- Hearing more on the BPUR press release: many sources tell us that all of the information provided is old news and that the company still won't be filing its BLA with the FDA until mid-2002; many view this event negatively as they see the company's credibility being damaged by the release of old news. We have a call into the company and are seeking to determine whether there is in fact any new and relevant information in today's release. 15:52 ET Biopure: questions about newness of news (BPUR) 11.20 +3.18: -- Update -- There appears to be some confusion regarding how much of today's BPUR news is in fact new news. There was a May 8, 2001 press release from the company which appears to have detailed the same efficacy data reported today. Today's press release also contains information about safety that did not appear in the May 8, 2001 release, but we're hearing skepticism about the importance of this information from several sources. 14:41 ET Biopure Corp announces Hemopure results, stock spikes (BPUR) 13.00 +4.98: Stock pops after the co announces that efficacy results from their Phase III clinical trial show an avoidance of red blood cell transfusions in 59.4% of the Hemopure-treated patients at 42 days post surgery, 70.3% at one week post surgery, and 96.3% on the day of surgery.